MREO NASDAQ Week ended 18 Sep 2026

Weekly Investor Report

Mereo BioPharma Group PLC ADR · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 0.303 USD
8.2% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is -2.2% below the Trend Line and sits at 4.7% of its 52-week range. The latest completed week returned 8.2%, after a 4.3% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is bullish with 42/100 conviction, while the latest news-sentiment score is 51/100. Near-term considerations: volume confirmation is below normal; earnings are due in 50d.

Setup score 24 out of 100
Latest Close 0.303 USD 18 Sep 2026
1W Return 8.2% latest completed week
4W Return 4.3% short-term follow-through
12W Return 2.2% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 0.4x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 42.68% based on similar historical setup states.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 8.2% Latest completed week; four-week move 4.3%. Indicator stack 0/48 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 42.68% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Bullish 42/100 conviction; expected move 100.0%. News sentiment 51/100 5 relevant articles in the latest sentiment read. Event risk 50d Next report is scheduled for 09 Nov 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -2.2% below the Trend Line and sits at 4.7% of its 52-week range. The latest completed week returned 8.2%, after a 4.3% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.4x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug 14 Aug 21 Aug 28 Aug 4 Sep 11 Sep 18 Sep
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2012-week average 0.23

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.20Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 4.3% over four weeks, 2.2% over 12 weeks, and -82.6% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W8.2%
4W4.3%
12W2.2%
26W-11.4%
52W-82.6%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.25Latest activity-pressure read.
Pressure change-76.3%Four-week change in activity pressure.
Leadership-66.66Latest relative-leadership reading.
RS change7.7%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 11 Sep 2026 Financial statements through 30 Jun 2026 Field coverage 64% Model confidence 64%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength64/100Blend of value, momentum, and quality. Underlying universe rank 37; rank 1 is best.
Value57/100Relative valuation strength. Underlying universe rank 44; rank 1 is best.
Quality55/100Profitability and accounting quality. Underlying universe rank 46; rank 1 is best.
Momentum57/100Medium-term price momentum. Underlying universe rank 44; rank 1 is best.
Growth57/100Revenue and earnings growth. Underlying universe rank 44; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-164.1%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-0.1%
Net share repurchases relative to market value.
Shareholder yield
-0.1%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.9x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

MREO shows bullish options pressure with a 42/100 conviction score, put-call volume ratio of 0.28, expected move of 100.0%, and Sharemaestro trend signal inactive.

Conviction42/100
Expected move100.0%
Put/call volume0.28
Pressure68
Speculation16
Volatility96
Trend agreement0
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment51/100

Weighted news tone is neutral across 5 relevant articles.

1 positive · 4 neutral · 0 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings50dNext report is scheduled for 09 Nov 2026; event risk rises as the date approaches.
Options expected move100.0%Nearest-chain priced movement where available.
52-week drawdown-87.2%Distance below the 52-week high.
13-week volatility10.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+23.6%Week of 29 May.
Worst week-13.8%Week of 24 Apr.
Latest week+8.2%Week of 18 Sep.

Shape of recent returns

Strong gains7
Modest gains4
Flat weeks0
Modest losses5
Sharp losses10
Recent vol10.2%13-week weekly-return volatility.
Base vol14.8%52-week weekly-return volatility.
Up/down split22/30Count of positive and negative weeks in the 52-week window.
Average skew9.6% / -9.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape18/100

Trend, activity pressure, participation, and risk combine to a 18/100 tape read.

 Indicator analysis33/100

Latest 12-week confirmation: trend 0/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.20; No reversal markers Next-Week ExpectancyNegative 42.68%

Next-week expectancy is negative with a 42.68% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors58/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 81 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options42/100

MREO shows bullish options pressure with a 42/100 conviction score, put-call volume ratio of 0.28, expected move of 100.0%, and Sharemaestro trend signal inactive.

Bullish · Call-side pressure · Expected move 100.0% Sentiment51/100

Weighted news tone is neutral across 5 relevant articles.

Cantor Fitzgerald reiterates Mereo BioPharma stock Overweight rating at $3 By Investing.com Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50d

Next report is scheduled for 09 Nov 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
18 Sep 20260.303 USD8.2%0.3099 USD2.25 USD0.25-66.668.1MOff
11 Sep 20260.28 USD12.0%0.3139 USD2.26 USD0.29-70.059.6MOff
4 Sep 20260.25 USD-1.0%0.317 USD2.26 USD0.54-74.455.9MOff
28 Aug 20260.2525 USD-13.1%0.3228 USD2.27 USD0.82-75.075.9MOff
21 Aug 20260.2904 USD-8.9%0.329 USD2.28 USD1.08-72.215.1MOff
14 Aug 20260.3189 USD7.6%0.3369 USD2.29 USD1.06-71.19178.1MOff
7 Aug 20260.2963 USD-13.5%0.3476 USD2.29 USD0.95-73.803.5MOff
31 Jul 20260.3427 USD19.1%0.3542 USD2.30 USD0.99-69.018.0MOff
24 Jul 20260.2878 USD-7.2%0.3598 USD2.31 USD0.97-74.603.0MOff
17 Jul 20260.3101 USD-7.4%0.4272 USD2.31 USD0.96-73.883.6MOff
10 Jul 20260.335 USD0.1%0.4836 USD2.32 USD0.87-73.766.3MOff
3 Jul 20260.3347 USD12.8%0.5447 USD2.32 USD0.72-74.015.7MOff
26 Jun 20260.2966 USD-4.1%0.6022 USD2.33 USD0.62-77.889.8MOff
19 Jun 20260.3094 USD1.4%0.6547 USD2.34 USD0.66-78.917.5MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context